AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05223335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricagrelor
Description: 180 mg bolus then 90 mg twice daily
Study NCT05554523 — intervention group
Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging
Study NCT05574114 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bridging radiotherapy (BRT)
Description: RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
Study NCT05574114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy
Description: Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
Study NCT05574114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell product
Description: Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
Study NCT06147453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobika OPEP device
Description: 16 week twice daily use of the Aerobika OPEP device
Study NCT04707716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cementation
Description: cement retained implant crown
Study NCT05995171 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL
Study NCT04662034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMIC
Description: The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
Study NCT05475613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downstaging procedures containing immunotherapy
Description: Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
Study NCT05475613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
Study NCT06281678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
Study NCT04662034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
Study NCT04662034 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
Study NCT05122143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)
Study NCT05412121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention.
Study NCT05456022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
Description: Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying \< 4 % _ Purity (HPLC) > 95 %
Study NCT05456022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
Description: Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
Study NCT06301399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
Description: Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
Study NCT05604235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic upper limb strength exercise treatment
Description: A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. It will take approximately 30 minutes.
Study NCT05604235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with passive and active mobilization of the upper limb.
Description: A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulo-humeral complex and neurodynamics, where mobilizations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
Study NCT06339983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Scar Mobilization Therapy:
Description: In this therapy, deep pressure on some point of the area of the scar will be given which will be perpendicular to the skin and will be followed by skin rolling
Study NCT06523595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for Oral Administration.
Study NCT06523595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets for Oral Administration.
Study NCT05624255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmologic consultation
Description: Complete ophthalmologic examination including angio-OCT
Study NCT06635226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID110521156
Description: ID110521156 capsules taken orally once daily
Study NCT06635226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of 110521156
Description: ID110521156 placebo capsules taken orally once daily
Study NCT05328115 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALZ-101
Description: Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
Study NCT06339983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Cupping Therapy:
Description: A disposable plastic cup (5cm) will be positioned at THE selected area of the cesarean scar. Then, negative pressure will be applied using a mechanical vacuum pump, the cup will be gently slid around the selected area rhythmically to get a massage-like effect
Study NCT05456022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin chemotherapeutic drug as a positive control
Description: Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
Study NCT05328115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injections of adjuvanted placebo.
Study NCT06476964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsies
Description: Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
Study NCT06555432 — intervention group
Intervention type: DRUG
Intervention: LIVTENCITY
Description: LIVTENCITY tablet.
Study NCT06187675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Lifestyle Intervention Program
Description: Nutrition and Exercise components for pregnancy
Study NCT06187675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise Lifestyle Intervention Program
Description: Nutrition and Exercise components for pregnancy
Study NCT06495970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gradient Denervation System
Description: The Gradient Denervation System delivers ultrasound ablation to planned locations in the pulmonary artery to down-regulate the sympathetic nervous drive. The system includes a sterile, single-use catheter that is designed to centrally position the transducer within the arterial target zone for consistency of ablation.
Study NCT05275049 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT plus translingual stimulation device
Description: PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
Study NCT05275049 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PT plus translingual stimulation control device
Description: Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
Study NCT06443697 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a secondary analysis and no intervention is implemented.
Study NCT06398808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm1
Description: ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
Study NCT06398808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2
Description: ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
Study NCT05650528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QG101-23-0 capsules
Description: Single and Multiple Dose for oral
Study NCT01733134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
Study NCT01733134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patient in the placebo group will receive tolvaptan in addition to standard therapy
Study NCT04833205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
Study NCT06148766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Health Eternal Renewal Regenerating Face Cream with Royal Jelly and Bee Venom
Description: Face cream containing manuka honey, royal bee jelly, and bee venom.
Study NCT05122143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: No treatment
Study NCT06321159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: mobile application for diet, exercises and medication adherence
Study NCT05990881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: Patients in this group will receive an injection of Botulinum toxin.
Study NCT05990881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care corticosteroid injections
Description: Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
Study NCT05634889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation
Description: No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery. Chest wall radiotherapy after mastectomy only in case of wide spread multifocality.
Study NCT05123274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Mobilization
Description: Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.
Study NCT05123274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Care Counseling
Description: Twenty-minute individual counseling session focused on HIV medical care
Study NCT05211830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXR1096 cream
Description: Skin cream to be applied twice a day to a predefined area of the skin
Study NCT05650528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single and Multiple Dose for oral
Study NCT05211830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Skin cream to be applied twice a day to a predefined area of the skin
Study NCT05485831 — intervention group
Intervention type: DRUG
Intervention: Epidiolex 100 mg/mL Oral Solution
Description: As prescribed in routine clinical practice in Italy.
Study NCT05035511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
Study NCT06537466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
Study NCT06537466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Ketogenic Diet
Description: The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
Study NCT05704699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTRE
Description: eating between 0800h and 1600h daily
Study NCT06568081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SloMo
Description: SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face sessions, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.
Study NCT06441955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-Boosted Nirmatrelvir (Paxlovid)
Description: Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment.
Study NCT06441955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Physiological Evaluation
Description: Common Medical laboratory work-up, Cancer screening test, Biomarkers, tissue biopsy, blood specimen, diagnostic imagining, Sensitivity and Specificity, HIV PCR, Viral load ( antigen), CD4- T cell count, while implementation of social mediators of prevention, promotion studies and conceptual models and quality of care.
Study NCT06441955 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna COVID-19 Vaccine
Description: Single dose, 0.25 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine
Study NCT05704699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eTRE with BISC
Description: eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
Study NCT06441955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychological
Description: Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
Study NCT06441955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral (e.g., Psychotherapy, Lifestyle Counseling)
Description: Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
Study NCT06441955 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetic (including gene transfer, stem cell and recombinant DNA)
Description: Full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time to address the intersection of genomics and health disparities, recognizing that genetic variations can contribute to health disparities in several ways. Understanding these genetic contributions to health disparities is crucial for developing targeted interventions and personalized healthcare strategies that can help address these disparities. genetics, epidemiology, public health, and social sciences, the study aims to shed light on the complex interplay between genomics and health equity. To evaluate cellular errors and the effects of myocardial DNA, you may need to consider tests such as DNA sequence.